|
1
|
Anari F, Ramamurthy C and Zibelman M:
Impact of tumor microenvironment composition on therapeutic
responses and clinical outcomes in cancer. Future Oncol.
14:1409–1421. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huh JW, Lee JH and Kim HR: Prognostic
significance of tumor-infiltrating lymphocytes for patients with
colorectal cancer. Arch Surg. 147:366–372. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density, and location of immune
cells within human colorectal tumors predict clinical outcome.
Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Teng F, Mu D, Meng X, Kong L, Zhu H, Liu
S, Zhang J and Yu J: Tumor infiltrating lymphocytes (TILs) before
and after neoadjuvant chemoradiotherapy and its clinical utility
for rectal cancer. Am J Cancer Res. 5:2064–2074. 2015.PubMed/NCBI
|
|
5
|
Lee WS, Kang M, Baek JH, Lee JI and Ha SY:
Clinical impact of tumor-infiltrating lymphocytes for survival in
curatively resected stage IV colon cancer with isolated liver or
lung metastasis. Ann Surg Oncol. 20:697–702. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kwak Y, Koh J, Kim DW, Kang SB, Kim WH and
Lee HS: Immunoscore encompassing CD3+ and
CD8+ T cell densities in distant metastasis is a robust
prognostic marker for advanced colorectal cancer. Oncotarget.
7:81778–81790. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yasuda K, Nirei T, Sunami E, Nagawa H and
Kitayama J: Density of CD4(+) and CD8(+) T lymphocytes in biopsy
samples can be a predictor of pathological response to
chemoradiotherapy (CRT) for rectal cancer. Radiat Oncol. 6:492011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Halama N, Michel S, Kloor M, Zoernig I,
Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G,
Luber B, et al: Localization and density of immune cells in the
invasive margin of human colorectal cancer liver metastases are
prognostic for response to chemotherapy. Cancer Res. 71:5670–5677.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tanis E, Julié C, Emile JF, Mauer M,
Nordlinger B, Aust D, Roth A, Lutz MP, Gruenberger T, Wrba F, et
al: Prognostic impact of immune response in resectable colorectal
liver metastases treated by surgery alone or surgery with
perioperative FOLFOX in the randomised EORTC study 40983. Eur J
Cancer. 51:2708–2717. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Foell J, Hewes B and Mittler RS: T cell
costimulatory and inhibitory receptors as therapeutic targets for
inducing anti-tumor immunity. Curr Cancer Drug Targets. 7:55–70.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li J and Gu J: Efficacy and safety of PD-1
inhibitors for treating advanced melanoma: A systematic review and
meta-analysis. Immunotherapy. 10:1293–1302. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Valecha GK, Vennepureddy A, Ibrahim U,
Safa F, Samra B and Atallah JP: Anti-PD-1/PD-L1 antibodies in
non-small cell lung cancer: The era of immunotherapy. Expert Rev
Anticancer Ther. 17:47–59. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ishii N, Takahashi T, Soroosh P and
Sugamura K: OX40-OX40 ligand interaction in T-cell-mediated
immunity and immunopathology. Adv Immunol. 105:63–98. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Croft M, So T, Duan W and Soroosh P: The
significance of OX40 and OX40L to T-cell biology and immune
disease. Immunol Rev. 229:173–191. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gramaglia I, Weinberg AD, Lemon M and
Croft M: Ox-40 ligand: A potent costimulatory molecule for
sustaining primary CD4 T cell responses. J Immunol. 161:6510–6517.
1998.PubMed/NCBI
|
|
16
|
Gramaglia I, Jember A, Pippig SD, Weinberg
AD, Killeen N and Croft M: The OX40 costimulatory receptor
determines the development of CD4 memory by regulating primary
clonal expansion. J Immunol. 165:3043–3050. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bansal-Pakala P, Halteman BS, Cheng MH and
Croft M: Costimulation of CD8 T cell responses by OX40. J Immunol.
172:4821–4825. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vu MD, Xiao X, Gao W, Degauque N, Chen M,
Kroemer A, Killeen N, Ishii N and Li XC: OX40 costimulation turns
off Foxp3+ Tregs. Blood. 110:2501–2510. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
So T and Croft M: Cutting edge: OX40
inhibits TGF-beta- and antigen-driven conversion of naive CD4 T
cells into CD25+Foxp3+ T cells. J Immunol.
179:1427–1430. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weinberg AD, Rivera MM, Prell R, Morris A,
Ramstad T, Vetto JT, Urba WJ, Alvord G, Bunce C and Shields J:
Engagement of the OX-40 receptor in vivo enhances antitumor
immunity. J Immunol. 164:2160–2169. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Piconese S, Valzasina B and Colombo MP:
OX40 triggering blocks suppression by regulatory T cells and
facilitates tumor rejection. J Exp Med. 205:825–839. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pan PY, Zang Y, Weber K, Meseck ML and
Chen SH: OX40 ligation enhances primary and memory cytotoxic T
lymphocyte responses in an immunotherapy for hepatic colon
metastases. Mol Ther. 6:528–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tanaka Y, Takahashi Y, Tanaka R, Miyagi T,
Saito M and Fukushima T: Association of high levels of plasma OX40
with acute adult T-cell leukemia. Int J Hematol. 109:319–327. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Weinberg AD, Wegmann KW, Funatake C and
Whitham RH: Blocking OX-40/OX-40 ligand interaction in vitro and in
vivo leads to decreased T cell function and amelioration of
experimental allergic encephalomyelitis. J Immunol. 162:1818–1826.
1999.PubMed/NCBI
|
|
25
|
Weiss A, Wiskocil RL and Stobo JD: The
role of T3 surface molecules in the activation of human T cells: A
two-stimulus requirement for IL 2 production reflects events
occurring at a pre-translational level. J Immunol. 133:123–128.
1984.PubMed/NCBI
|
|
26
|
Hayashi K, Nagasaki E, Kan S, Ito M,
Kamata Y, Homma S and Aiba K: Gemcitabine enhances
rituximab-mediated complement-dependent cytotoxicity to B cell
lymphoma by CD20 upregulation. Cancer Sci. 107:682–689. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Higgins LM, McDonald SA, Whittle N,
Crockett N, Shields JG and MacDonald TT: Regulation of T cell
activation in vitro and in vivo by targeting the OX40-OX40 ligand
interaction: Amelioration of ongoing inflammatory bowel disease
with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG
fusion protein. J Immunol. 162:486–493. 1999.PubMed/NCBI
|
|
29
|
Sadun RE, Hsu WE, Zhang N, Nien YC,
Bergfeld SA, Sabzevari H, Lutsiak ME, Khawli L, Hu P and Epstein
AL: Fc-mOX40L fusion protein produces complete remission and
enhanced survival in 2 murine tumor models. J Immunother.
31:235–245. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Okuma Y, Hosomi Y, Nakahara Y, Watanabe K,
Sagawa Y and Homma S: High plasma levels of soluble programmed cell
death ligand 1 are prognostic for reduced survival in advanced lung
cancer. Lung Cancer. 104:1–6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Weixler B, Cremonesi E, Sorge R, Muraro
MG, Delko T, Nebiker CA, Däster S, Governa V, Amicarella F, Soysal
SD, et al: OX40 expression enhances the prognostic significance of
CD8 positive lymphocyte infiltration in colorectal cancer.
Oncotarget. 6:37588–37599. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sagiv-Barfi I, Czerwinski DK, Levy S, Alam
IS, Mayer AT, Gambhir SS and Levy R: Eradication of spontaneous
malignancy by local immunotherapy. Sci Transl Med. 10(pii):
eaan44882018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Metzger TC, Long H, Potluri S, Pertel T,
Bailey-Bucktrout SL, Lin JC, Fu T, Sharma P, Allison JP and Feldman
RM: ICOS promotes the function of CD4+ effector T cells
during Anti-OX40-mediated tumor rejection. Cancer Res.
76:3684–3689. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gough MJ, Ruby CE, Redmond WL, Dhungel B,
Brown A and Weinberg AD: OX40 agonist therapy enhances CD8
infiltration and decreases immune suppression in the tumor. Cancer
Res. 68:5206–5215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mehrvarz Sarshekeh A, Overman MJ and
Kopetz S: Nivolumab in the treatment of microsatellite instability
high metastatic colorectal cancer. Future Oncol. 14:1869–1874.
2018. View Article : Google Scholar : PubMed/NCBI
|
